NCT00092274
Withdrawn
Phase 1
An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II
ConditionsLymphoma, Follicular
DrugsHuMax-CD20
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Lymphoma, Follicular
- Sponsor
- GlaxoSmithKline
- Locations
- 1
- Status
- Withdrawn
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Relapsed or refractory follicular lymphoma grade I-II
- •Tumor verified to be CD20 positive
- •CT scan showing demarcated lesions
Exclusion Criteria
- •Previous treatment with rituximab resulting in less than partial response
- •Previous radioimmunotherapy
- •Previous stem cell transplantation
- •Received the following treatments within 4 weeks prior to entering this study:
- •Anti-cancer therapy
- •Glucocorticosteroids unless less than 10 mg prednisolone/day
- •Radiotherapy
- •Received Mitomycin C or Nitrosoureas within 6 weeks prior to entering this trial
- •HIV positivity
- •Hepatitis B or hepatitis C
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Phase 1
HuMax-CD20 in Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00093314GlaxoSmithKline
Completed
Phase 2
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and AlemtuzumabLeukaemia, Lymphocytic, ChronicNCT00349349GlaxoSmithKline223
Completed
Phase 2
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to RituximabLymphoma, FollicularNCT00394836GlaxoSmithKline116
Active, not recruiting
Phase 2
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisAxial SpondyloarthritisNCT05445076Biocad250
Completed
Phase 1
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia ACongenital Bleeding DisorderHaemophilia ANCT01205724Novo Nordisk A/S27